Antiretroviral therapy-induced mitochondrial toxicity: Potential mechanisms beyond polymerase-γ inhibition

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 1, 2014, Pages 110-120

  Selvaraj, S ^a   Ghebremichael, M ^b   Li, M ^a   Foli, Y ^a   Langs Barlow, A ^a   Ogbuagu, A ^a   Barakat, L ^a   Tubridy, E ^c   Edifor, R ^a   Lam, W ^a   Cheng, Y C ^a   Paintsil, E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ABC TRANSPORTER; ANTIRETROVIRUS AGENT; DEOXYRIBONUCLEOTIDE; DEOXYRIBONUCLEOTIDE TRIPHOSPHATE; DNA DIRECTED DNA POLYMERASE GAMMA; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; MITOCHONDRIAL DNA; NUCLEOTIDE TRANSPORTER; PROTEIN KINASE; RIBONUCLEOTIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LACTIC ACIDOSIS; LIPODYSTROPHY; MALE; MITOCHONDRIAL TOXICITY; PANCYTOPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; THROMBOCYTOPENIA;

ANTI-HIV AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CASE-CONTROL STUDIES; DEOXYRIBONUCLEOTIDES; DNA, MITOCHONDRIAL; DNA-DIRECTED DNA POLYMERASE; FEMALE; GENE DOSAGE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIA; NUCLEOTIDE TRANSPORT PROTEINS; NUCLEOTIDES; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEOTIDES;

EID: 84902772537     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.64     Document Type: Article

References (50)

1. Yeni, P.G. et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 292, 251-265 (2004)
2. Lenert, L.A., Feddersen, M., Sturley, A. & Lee, D. Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection. Am. J. Med. 113, 229-232 (2002)
3. Powderly, W.G. Long-Term exposure to lifelong therapies. J. Acquir. Immune Defic. Syndr. 29 (suppl. 1), S28-S40 (2002)
4. Lewis, W. & Dalakas, M.C. Mitochondrial toxicity of antiviral drugs. Nat. Med. 1, 417-422 (1995)
5. Chen, C.H. & Cheng, Y.C. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2,3-dideoxycytidine. J. Biol. Chem. 264, 11934-11937 (1989)
6. Chen, C.H., Vazquez-Padua, M. & Cheng, Y.C. Effect of anti-human immunodeficiency virus nucleotide analogs on mitochondrial DNA and its implication for delayed toxicity. Mol. Pharmacol. 39, 625-628 (1991)
7. Brinkman, K., Smeitink, J.A., Romijn, J.A. & Reiss, P. Mitochondrial toxicity induced by nucleotide-Analogue reverse-Transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-Therapy-related lipodystrophy. Lancet 354, 1112-1115 (1999)
8. Maagaard, A. & Kvale, D. Long term adverse effects related to nucleotide reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity. Scand. J. Infect. Dis. 41, 808-817 (2009)
9. Cote, H.C. Possible ways nucleotide analogues can affect mitochondrial DNA content and gene expression during HIV therapy. Antivir. Ther. 10 (suppl. 2), M3-11 (2005)
10. Mallon, P.W. et al.; SAMA Investigators. In vivo, nucleotide reversetranscriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J. Infect. Dis. 191, 1686-1696 (2005)
11. McComsey, G., Tan, D.J., Lederman, M., Wilson, E. & Wong, L.J. Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS 16, 513-518 (2002)
12. Deng, W., Baki, L., Yin, J., Zhou, H. & Baumgarten, C.M. HIV protease inhibitors elicit volume-sensitive Cl-current in cardiac myocytes via mitochondrial ROS. J. Mol. Cell. Cardiol. 49, 746-752 (2010)
13. Blas-Garcia, A. et al. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 52, 115-125 (2010)
14. Apostolova, N., Gomez-Sucerquia, L.J., Moran, A., Alvarez, A., Blas-Garcia, A. & Esplugues, J.V. Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells. Br. J. Pharmacol. 160, 2069-2084 (2010)
15. Maagaard, A., Holberg-Petersen, M., Kollberg, G., Oldfors, A., Sandvik, L. & Bruun, J.N. Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients. Antivir. Ther. 11, 601-608 (2006)
16. Maagaard, A., Holberg-Petersen, M., Lovgarden, G., Holm, M., Pettersen, F.O. & Kvale, D. Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleotide reversetranscriptase inhibitors and those naive to antiretroviral treatment. J. Infect. Dis. 198, 1474-1481 (2008)
17. McComsey, G.A. et al. Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection. Antivir. Ther. 13, 715-722 (2008)
18. Van Rompay, A.R., Johansson, M. & Karlsson, A. Phosphorylation of nucleotides and nucleotide analogs by mammalian nucleotide monophosphate kinases. Pharmacol. Ther. 87, 189-198 (2000)
19. J ordheim, L.P. & Dumontet, C. Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim. Biophys. Acta 1776, 138-159 (2007)
20. Huber-Ruano, I. & Pastor-Anglada, M. Transport of nucleotide analogs across the plasma membrane: a clue to understanding drug-induced cytotoxicity. Curr. Drug Metab. 10, 347-358 (2009)
21. Kock, K. et al. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clin. Pharmacokinet. 46, 449-470 (2007)
22. Zhang, W. et al. Analysis of deoxyribonucleotide pools in human cancer cell lines using a liquid chromatography coupled with tandem mass spectrometry technique. Biochem. Pharmacol. 82, 411-417 (2011)
23. McComsey, G.A. et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 19, 15-23 (2005)
24. Sharma, T.S. et al.; Pediatric HIV/AIDS Cohort Study (PHACS) Short communication: The relationship between mitochondrial dysfunction and insulin resistance in HIV-infected children receiving antiretroviral therapy. AIDS Res. Hum. Retroviruses 29, 1211-1217 (2013)
25. Cherry, C.L. et al. Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 42, 435-440 (2006)
26. Blanche, S. et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleotide analogues. Lancet 354, 1084-1089 (1999)
27. Hammond, E.L. et al. Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study. J. Clin. Virol. 27, 97-110 (2003)
28. Gerschenson, M., Shiramizu, B., LiButti, D.E. & Shikuma, C.M. Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals. Antivir. Ther. 10 (suppl. 2), M83-M89 (2005)
29. Oldfors, A., Holme, E., Tulinius, M. & Larsson, N.G. Tissue distribution and disease manifestations of the tRNA(Lys) A->G(8344) mitochondrial DNA mutation in a case of myoclonus epilepsy and ragged red fibres. Acta Neuropathol. 90, 328-333 (1995)
30. Kohler, J.J. & Lewis, W. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ. Mol. Mutagen. 48, 166-172 (2007)
31. Ferraro, P., Bianchi, V., Biasin, M.R. & Celotti, L. Deoxynucleotide pools and DNA synthesis in resting and PHA-stimulated human lymphocytes treated with mutagens. Exp. Cell Res. 199, 349-354 (1992)
32. Iwasaki, H., Huang, P., Keating, M.J. & Plunkett, W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 90, 270-278 (1997)
33. Sutinen, J. et al. Uridine supplementation for the treatment of antiretroviral therapy-Associated lipoatrophy: a randomized, double-blind, placebocontrolled trial. Antivir. Ther. 12, 97-105 (2007)
34. McComsey, G.A., ORiordan, M., Setzer, B., Lebrecht, D., Baron, E. & Walker, U.A. Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices. Eur. J. Clin. Nutr. 62, 1031-1037 (2008)
35. McComsey, G.A. et al.; AIDS Clinical Trials Group A5229 Team. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229. AIDS 24, 2507-2515 (2010)
36. Guallar, J.P. et al. Altered expression of nucleotide transporter genes (SLC28 and SLC29) in adipose tissue from HIV-1-infected patients. Antivir. Ther. 12, 853-863 (2007)
37. Kohler, J.J. et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab. Invest. 91, 852-858 (2011)
38. Hoschele, D. Cell culture models for the investigation of NRTI-induced mitochondrial toxicity. Relevance for the prediction of clinical toxicity. Toxicol. In Vitro 20, 535-546 (2006)
39. Sievers, M. et al. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleotide analogue reversetranscriptase inhibitor-Associated lipoatrophy. J. Infect. Dis. 200, 252-262 (2009)
40. Galluzzi, L. et al. Changes in mitochondrial RNA production in cells treated with nucleotide analogues. Antivir. Ther. 10, 191-195 (2005)
41. Lagathu, C. et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir. Ther. 12, 489-500 (2007)
42. Apostolova, N., Blas-Garcia, A. & Esplugues, J.V. Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-Ã inhibition. Trends Pharmacol. Sci. 32, 715-725 (2011)
43. Brinkman, K., ter Hofstede, H.J., Burger, D.M., Smeitink, J.A. & Koopmans, P.P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12, 1735-1744 (1998)
44. Kakuda, T.N. Pharmacology of nucleotide and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. 22, 685-708 (2000)
45. Tuttle, D.L. et al. Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. AIDS Res. Hum. Retroviruses 18, 353-362 (2002)
46. Cohen, S. et al. Simultaneous analysis of eight nucleotide triphosphates in cell lines by liquid chromatography coupled with tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 877, 3831-3840 (2009)
47. McComsey, G.A. et al.; AIDS Clinical Trials Group A5084. Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy. HIV Clin. Trials 9, 126-136 (2008)
48. Lu, L., Katsaros, D., Wiley, A., Rigault de la Longrais, I.A., Puopolo, M. & Yu, H. Expression of MDR1 in epithelial ovarian cancer and its association with disease progression. Oncol. Res. 16, 395-403 (2007)
49. Colombo, S. et al.; Swiss HIV Cohort Study. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet. Genomics 15, 599-608 (2005)
50. Ohishi, Y. et al. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin. Cancer Res. 8, 3767-3775 (2002)